1. Scrip
  2. >>Leadership

Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League

Bourla’s Total Package Exceeds $30m

 
• By Eleanor Malone and Kosh Naran

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Titans of Pharma 2023
• Source: Shutterstock

Every year, Scrip and In Vivo’s Titans Of Pharma infographic spotlights the executive compensation packages at big pharma, lining CEO and R&D chief remuneration up against other company metrics including sales, net profits, market cap and median employee compensation. Explore the interactive dashboard across multiple years and data points. Scroll on down for further charts and analysis.

The compensation figures provided in our data charts include base salary, bonus and long-term incentives (including equity awards) and are gathered from companies’ official filings. The list encompasses 20 biopharma companies with the highest revenues in the world

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.